First patient dosed in Onchilles’ Phase I/II trial of N17350
The study is structured to assess the anti-tumour efficacy, biomarker effects, recommended dose, safety and tolerability of N17350.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance